A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients With Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Latest Information Update: 09 Oct 2025
At a glance
- Drugs IPM 514 (Primary)
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Beijing Immupeutics Medicine Technology
Most Recent Events
- 09 Oct 2025 New trial record